Scrip Asks… What Does 2025 Hold For Biopharma?
Timely for this year’s J.P. Morgan conference, Citeline flagship publication Scrip continues in its annual review series “Scrip Asks”, where some of the most influential and important KOLs in the sector review the previous year, and predict outcomes for the next.
In Part 1 of the 2025 edition, focused on the state of the biopharma industry, Ali Pashazadeh, Treehill Partners CEO, starts the indepth article which is featuring renown industry leaders, with a look at the industry sentiment going into the new year.
He says “Going into 2025, the industry appears to finally have appreciated that things are not going to be ‘going back to normal’”.
Read the full article on Citeline: